EHA 2021 | Novel therapies on the horizon for MDS
Andrew Brunner
• 3 Jun 2021
Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, comments on the challenges of treating myelodysplastic syndromes (MDS), highlighting the approvals of luspatercept and oral decitabine. In particular, Dr Brunner highlights findings of the BMT CTN 1102 trial (NCT02016781) which demonstrated the benefit of allogeneic transplant in patients with MDS. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Andrew M. Brunner, MD, has participated in consultancy work for Novartis, Acceleron, Agios, BMS/Celgene and Takeda.
